Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency
NCT06851754Phase 3Recruiting
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Start
- Jul 2025
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of estradiol and progesterone in premature ovarian insufficiency (POI) (2 arms), sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development. Primary endpoint: Bone Mineral Density of the central skeleton (lumbar spine) at 2 years. Started Jul 2025; status: recruiting.
02
Drugs
estradiolprogesterone
03
Conditions
premature ovarian insufficiency (POI)
Beyond the preview
Go deeper on NCT06851754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851754.